Ignite Creation Date:
2025-12-24 @ 12:43 PM
Ignite Modification Date:
2025-12-27 @ 10:07 PM
Study NCT ID:
NCT07088861
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-11-18
First Post:
2025-07-21
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Validation of the 9th AJCC Staging System for NPC in Non-High-Incidence Areas in China
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000077274', 'term': 'Nasopharyngeal Carcinoma'}], 'ancestors': [{'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D009303', 'term': 'Nasopharyngeal Neoplasms'}, {'id': 'D010610', 'term': 'Pharyngeal Neoplasms'}, {'id': 'D010039', 'term': 'Otorhinolaryngologic Neoplasms'}, {'id': 'D006258', 'term': 'Head and Neck Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009302', 'term': 'Nasopharyngeal Diseases'}, {'id': 'D010608', 'term': 'Pharyngeal Diseases'}, {'id': 'D009057', 'term': 'Stomatognathic Diseases'}, {'id': 'D010038', 'term': 'Otorhinolaryngologic Diseases'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'RETROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 1401}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2011-01-26', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-07', 'completionDateStruct': {'date': '2025-12-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-11-16', 'studyFirstSubmitDate': '2025-07-21', 'studyFirstSubmitQcDate': '2025-07-21', 'lastUpdatePostDateStruct': {'date': '2025-11-18', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2025-07-28', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-12-31', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Overall Survival', 'timeFrame': '10 years', 'description': 'Time from initiation of treatment to death from any cause or the date of last follow-up.'}], 'secondaryOutcomes': [{'measure': 'Progression-Free Survival', 'timeFrame': '10 year', 'description': 'Time from initiation of treatment to documented disease progression or death, whichever occurs first.'}, {'measure': 'Locoregional Recurrence-Free Survival', 'timeFrame': '10 year', 'description': 'Time from initiation of treatment to recurrence at the primary tumor site or regional lymph nodes.'}, {'measure': 'Distant Metastasis-Free Survival', 'timeFrame': '10 year', 'description': 'Time from initiation of treatment to the first occurrence of distant metastasis.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Nasopharyngeal carcinoma', 'The 9th Edition AJCC/UICC Staging System', 'long-term follow-up', 'Multicentre'], 'conditions': ['Nasopharyngeal Carcinoma (NPC)']}, 'referencesModule': {'references': [{'pmid': '31586896', 'type': 'BACKGROUND', 'citation': 'Wu LR, Zhang XM, Xie XD, Lu Y, Wu JF, He X. Validation of the 8th edition of AJCC/UICC staging system for nasopharyngeal carcinoma: Results from a non-endemic cohort with 10-year follow-up. Oral Oncol. 2019 Nov;98:141-146. doi: 10.1016/j.oraloncology.2019.09.029. Epub 2019 Oct 4.'}, {'pmid': '34111416', 'type': 'BACKGROUND', 'citation': 'Chen YP, Liu X, Zhou Q, Yang KY, Jin F, Zhu XD, Shi M, Hu GQ, Hu WH, Sun Y, Wu HF, Wu H, Lin Q, Wang H, Tian Y, Zhang N, Wang XC, Shen LF, Liu ZZ, Huang J, Luo XL, Li L, Zang J, Mei Q, Zheng BM, Yue D, Xu J, Wu SG, Shi YX, Mao YP, Chen L, Li WF, Zhou GQ, Sun R, Guo R, Zhang Y, Xu C, Lv JW, Guo Y, Feng HX, Tang LL, Xie FY, Sun Y, Ma J. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2021 Jul 24;398(10297):303-313. doi: 10.1016/S0140-6736(21)01123-5. Epub 2021 Jun 7.'}, {'pmid': '37871379', 'type': 'BACKGROUND', 'citation': 'Yang X, Ren H, Li Z, Peng X, Fu J. Combinations of radiotherapy with immunotherapy in nasopharyngeal carcinoma. Int Immunopharmacol. 2023 Dec;125(Pt A):111094. doi: 10.1016/j.intimp.2023.111094. Epub 2023 Oct 23.'}, {'pmid': '40468367', 'type': 'BACKGROUND', 'citation': 'Cai S, Huang Z, Chen Z, Li Y, Su J, Chen R, Xu S, Wang J, Qiu S. A nomogram integrating clinical stage and pre-EBV DNA to identify the cycles of induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Radiat Oncol. 2025 Jun 4;20(1):93. doi: 10.1186/s13014-025-02672-1.'}, {'pmid': '31654937', 'type': 'BACKGROUND', 'citation': "Lu T, Hu Y, Xiao Y, Guo Q, Huang SH, O'Sullivan B, Fang Y, Zong J, Chen Y, Lin S, Chen Y, Pan J. Prognostic value of radiologic extranodal extension and its potential role in future N classification for nasopharyngeal carcinoma. Oral Oncol. 2019 Dec;99:104438. doi: 10.1016/j.oraloncology.2019.09.030. Epub 2019 Oct 22."}, {'pmid': '39938522', 'type': 'BACKGROUND', 'citation': 'Jiang W, Wang GY, Qin GJ, Zhang WQ, Zhu XD, Han YQ, Lei F, Shen LF, Yang KY, Cui CY, Tang LL, Mao YP, Chen L, Guo R, Li L, Wu Z, Xu GQ, Zhou Q, Huang J, Huang SH, Li JB, Liu LZ, Ma J, Du XJ. Advanced image-identified extranodal extension of retropharyngeal lymph nodes in the refinement of N classification for nasopharyngeal carcinoma. Cell Rep Med. 2025 Feb 18;6(2):101942. doi: 10.1016/j.xcrm.2025.101942. Epub 2025 Feb 11.'}, {'pmid': '34718052', 'type': 'BACKGROUND', 'citation': "Chin O, Yu E, O'Sullivan B, Su J, Tellier A, Siu L, Waldron J, Kim J, Hansen A, Hope A, Cho J, Giuliani M, Ringash J, Spreafico A, Bratman S, Hosni A, Hahn E, Tong L, Xu W, Huang SH. Prognostic importance of radiologic extranodal extension in nasopharyngeal carcinoma treated in a Canadian cohort. Radiother Oncol. 2021 Dec;165:94-102. doi: 10.1016/j.radonc.2021.10.018. Epub 2021 Oct 27."}, {'pmid': '33516790', 'type': 'BACKGROUND', 'citation': "Mao Y, Wang S, Lydiatt W, Shah JP, Colevas AD, Lee AWM, O'Sullivan B, Guo R, Luo W, Chen Y, Tian L, Tang L, Sun Y, Liu L, Ren J, Ma J. Unambiguous advanced radiologic extranodal extension determined by MRI predicts worse outcomes in nasopharyngeal carcinoma: Potential improvement for future editions of N category systems. Radiother Oncol. 2021 Apr;157:114-121. doi: 10.1016/j.radonc.2021.01.015. Epub 2021 Jan 28."}, {'pmid': '39388190', 'type': 'BACKGROUND', 'citation': "Pan JJ, Mai HQ, Ng WT, Hu CS, Li JG, Chen XZ, Chow JCH, Wong E, Lee V, Ma LY, Guo QJ, Liu Q, Liu LZ, Xu TT, Gong XC, Qiang MY, Au KH, Liu TC, Chiang CL, Xiao YP, Lin SJ, Chen YB, Guo SS, Wong CHL, Tang LQ, Xu ZY, Jia YZ, Peng WS, Hu LP, Lu TZ, Jiang F, Cao CN, Xu W, Ma J, Blanchard P, Williams M, Glastonbury CM, King AD, Patel SG, Seethala RR, Colevas AD, Fan DM, Chua MLK, Huang SH, O'Sullivan B, Lydiatt W, Lee AWM. Ninth Version of the AJCC and UICC Nasopharyngeal Cancer TNM Staging Classification. JAMA Oncol. 2024 Oct 10;10(12):1627-35. doi: 10.1001/jamaoncol.2024.4354. Online ahead of print."}, {'pmid': '31650266', 'type': 'BACKGROUND', 'citation': 'Huang CL, Guo R, Li JY, Xu C, Mao YP, Tian L, Lin AH, Sun Y, Ma J, Tang LL. Nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: clinical outcomes and patterns of failure among subsets of 8th AJCC stage IVa. Eur Radiol. 2020 Feb;30(2):816-822. doi: 10.1007/s00330-019-06500-5. Epub 2019 Oct 24.'}, {'pmid': '38242125', 'type': 'BACKGROUND', 'citation': 'Du XJ, Wang GY, Zhu XD, Han YQ, Lei F, Shen LF, Yang KY, Chen L, Mao YP, Tang LL, Li L, Wu Z, Xu GQ, Zhou Q, Huang J, Guo R, Zhang Y, Liu X, Zhou GQ, Li WF, Xu C, Lin L, Chen YP, Chen FP, Liang XY, Chen SY, Li SQ, Cui CY, Li JB, Ren J, Chen MY, Liu LZ, Sun Y, Ma J. Refining the 8th edition TNM classification for EBV related nasopharyngeal carcinoma. Cancer Cell. 2024 Mar 11;42(3):464-473.e3. doi: 10.1016/j.ccell.2023.12.020. Epub 2024 Jan 18.'}, {'pmid': '40079940', 'type': 'BACKGROUND', 'citation': 'Liang YL, Liu X, Shen LF, Hu GY, Zou GR, Zhang N, Chen CB, Chen XZ, Zhu XD, Yuan YW, Yang KY, Jin F, Hu WH, Xie FY, Huang Y, Han F, Tang LL, Mao YP, Lu LX, Sun R, He YX, Zhou YY, Long GX, Tang J, Chen LS, Zong JF, Jin T, Li L, Lin J, Huang J, Gong XY, Zhou GQ, Chen L, Li WF, Chen YP, Xu C, Lin L, Huang SH, Huang SW, Wang YQ, Huang CL, Feng HX, Hou M, Chen CH, Zheng SF, Li YQ, Hong SB, Jie YS, Li H, Yun JP, Zang SB, Liu SR, Lin QG, Li HJ, Tian L, Liu LZ, Zhao HY, Li JB, Lin AH, Liu N, Zhang Y, Guo R, Ma J, Sun Y. Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial. JAMA. 2025 May 13;333(18):1589-1598. doi: 10.1001/jama.2025.1132.'}, {'pmid': '40016735', 'type': 'BACKGROUND', 'citation': 'Wang Z, Sun Y, Wang Q, Chai Y, Sun J, Zhang X, Wang Q, Wang W, Wang P. Induction chemotherapy plus camrelizumab combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma in non-endemic areas: a phase 2 clinical trial in North China. BMC Med. 2025 Feb 27;23(1):126. doi: 10.1186/s12916-025-03964-9.'}, {'pmid': '35639144', 'type': 'BACKGROUND', 'citation': 'Li S, Luo C, Huang W, Zhu S, Ruan G, Liu L, Li H. Value of skull base invasion subclassification in nasopharyngeal carcinoma: implication for prognostic stratification and use of induction chemotherapy. Eur Radiol. 2022 Nov;32(11):7767-7777. doi: 10.1007/s00330-022-08864-7. Epub 2022 May 31.'}]}, 'descriptionModule': {'briefSummary': "Background:\n\nNasopharyngeal carcinoma (NPC) is a malignancy with marked geographic variation, with over 80% of global cases found in Southeast and East Asia. However, the characteristics of NPC in non-high-incidence areas in China (such as Jiangsu, Zhejiang, and Anhui provinces) remain understudied. These regions show different EBV prevalence, environmental exposures, and socioeconomic factors compared to endemic regions, which may affect tumor biology and treatment response. The 9th edition AJCC/UICC TNM staging system (TNM-9) introduces critical revisions to improve risk stratification-particularly in N classification-based on new imaging and biological insights like radiologic extranodal extension (rENE). However, its applicability to non-high-incidence populations remains unclear and requires validation.\n\nObjectives:\n\nTo validate the prognostic performance of TNM-9 compared to TNM-8 in non-high-incidence NPC populations, assessing survival outcomes (OS, PFS, DMFS, LRFS) and model performance (C-index, AUC, etc.).\n\nTo explore subtypes among locally advanced NPC (LA-NPC) under TNM-9 for potential treatment intensification or de-escalation strategies.\n\nTo assess the clinical significance of ENE among N3 patients and its impact on survival and treatment response.\n\nTo develop risk models based on anatomic features of advanced nodal involvement to enhance personalized treatment planning.\n\nDesign and Methods:\n\nStudy Type: Multicenter retrospective cohort study. Sites: Tertiary cancer centers in Jiangsu, Zhejiang, and Anhui. Sample Size: Approximately 1,401 patients diagnosed between 2011 and 2023. Inclusion Criteria: Adults aged 18-75 with newly diagnosed, untreated NPC from non-high-incidence regions who underwent complete MRI and standard chemoradiotherapy.\n\nExclusion Criteria: Prior treatment, severe comorbidities, pregnancy, or incomplete data.\n\nTreatment:\n\nPatients received standard radiotherapy-based treatment according to CSCO guidelines, including IMRT with or without induction/adjuvant chemotherapy or targeted/immunotherapy.\n\nEndpoints:\n\nPrimary: Overall Survival (OS) Secondary: Progression-Free Survival (PFS), Distant Metastasis-Free Survival (DMFS), and Local Recurrence-Free Survival (LRFS) Model Metrics: Harrell's C-index, time-dependent ROC, Brier score\n\nStatistical Analysis:\n\nKaplan-Meier survival curves, log-rank tests, univariable and multivariable Cox regression. Prognostic models compared via performance metrics. Bootstrap used for internal validation. Subgroup analyses explore survival differences under TNM-9 stratification.\n\nSafety Evaluation:\n\nThough retrospective, adverse events are extracted from clinical records, including grade ≥3 toxicities from radiotherapy, chemotherapy, and immunotherapy. Particular attention is given to immune-related adverse events (irAEs) and treatment discontinuations.\n\nEthics and Data Handling:\n\nThe study complies with the Declaration of Helsinki. No experimental interventions are involved. All data are anonymized and securely stored; informed consent is obtained as per GCP guidelines.\n\nSignificance:\n\nThis study addresses the gap in NPC staging validation in non-high-incidence populations. It aims to confirm the utility of TNM-9 in real-world Chinese cohorts outside high-incidence areas and explore refined treatment strategies for LA-NPC. The findings could impact staging policy, risk stratification, and clinical decision-making, supporting more personalized NPC management across diverse regions.", 'detailedDescription': 'Nasopharyngeal Carcinoma (NPC) is a malignant tumor with distinct geographical distribution characteristics, with over 80% of global cases concentrated in East Asia and Southeast Asia. These two regions-particularly southern China (including Guangdong, Guangxi, Hong Kong, and Taiwan), Malaysia, Vietnam, and the Philippines-are high-incidence areas for NPC and prioritize NPC as a key malignant tumor for prevention and control. In other parts of the world, such as Europe and North America, the incidence of NPC is relatively low. In non-endemic regions of China (e.g., northern and eastern China), significant gaps in knowledge remain regarding NPC\'s epidemiological characteristics, etiological mechanisms, and clinical management strategies. Epidemiological studies have shown that differences in Epstein-Barr virus (EBV) seropositivity rates, dietary patterns, and environmental exposures between populations in non-endemic and endemic regions may lead to significant variations in tumor biological behavior and treatment responses.\n\nMore critically, over 70% of patients are diagnosed at the locally advanced NPC (LA-NPC) stage initially. Even with the current standard treatment regimen-induction chemotherapy (IC) combined with concurrent chemoradiotherapy (CCRT)-20%-30% of patients still face recurrence or metastasis, highlighting the urgency of optimizing treatment strategies. Notably, previous large-scale clinical studies have been based exclusively on populations in endemic regions, while data from non-endemic regions have long been overlooked. The unique clinicopathological features and potential differential treatment needs of NPC in non-endemic regions urgently require clarification through targeted research.\n\nAccurate AJCC/UICC staging serves as the cornerstone for formulating individualized treatment strategies and assessing prognosis. The newly released 9th edition AJCC/UICC Staging System (hereafter referred to as TNM-9) in 2024 has achieved key breakthroughs, addressing the limitations of TNM-8.\n\nFirst, TNM-9 has optimized the N staging. Extranodal Extension (ENE) refers to the infiltration of tumor cells beyond the lymph node capsule into surrounding tissues. In recent years, the prognostic value of radiological Extranodal Extension (rENE) in NPC has received widespread attention. rENE is typically evaluated via magnetic resonance imaging (MRI) and classified into the following grades:\n\nG1-rENE: MRI shows tumor invasion of surrounding adipose tissue without involvement of adjacent structures (e.g., muscles, neurovascular structures, skin).\n\nG2-rENE: Multiple adjacent lymph nodes fuse to form a mass, with loss of normal anatomical spaces.\n\nG3-rENE: Tumor significantly invades adjacent structures beyond perinodal adipose tissue (e.g., muscles, neurovascular structures, skin, or salivary glands). This grade indicates that the tumor has penetrated the lymph node capsule and directly invaded critical surrounding tissues, correlating with a higher risk of distant metastasis and poorer prognosis.\n\nAi QY and King AD conducted a retrospective analysis of MRI data from 546 NPC patients, evaluating ENE, lymph node size, location, and necrosis. They found that advanced ENE (invading muscles or skin) significantly increased the risk of distant metastasis (HR=4.742, p\\<0.001), regional recurrence rate (p=0.014), and mortality risk (HR=2.672, p\\<0.001). Its prognostic significance was comparable to that of stage N3, leading the authors to recommend its inclusion in the N3 classification. Canadian scholar Chin et al. also validated the prognostic role of ENE in NPC, emphasizing its general applicability in Western populations.\n\nHowever, controversy remains regarding whether ENE in retropharyngeal lymph nodes (RLNs) should also be classified as N3. Jiang et al. analyzed 4485 patients with non-metastatic NPC and found that patients with stage N1-2 and advanced RLN ENE had a significantly better 5-year overall survival (OS) than those with stage N3 (HR=0.60, 95% CI: 0.38-0.93). Additionally, in multivariate analysis, advanced RLN ENE was not an independent prognostic factor (HR=1.08, p=0.21).\n\nIn summary, domestic and international studies consistently confirm that \\*\\*advanced ENE\\*\\* (definite invasion of adjacent muscles, skin, and/or neurovascular structures) is an independent poor prognostic factor for all endpoints (HR=1.67; 95% CI=1.26-2.19). Based on this evidence, the 9th edition N staging incorporates radiologically confirmed advanced lymph node invasion into the definition of N3 for the first time. The new N3 criteria are explicitly defined as unilateral or bilateral cervical lymph node metastasis meeting any of the following conditions:\n\n1. Maximum diameter \\> 6 cm;\n2. Lymph nodes extending inferiorly beyond the caudal margin of the cricoid cartilage;\n3. Presence of advanced ENE (i.e., invasion of adjacent muscles, skin, or neurovascular bundles).\n\nTNM-9 has also made important adjustments to the overall staging system, reorganizing the overall stages and refining subgroups:\n\n* The scope of Stage I has been expanded to include more patients.\n* Significant changes have been made for patients with locally advanced disease: most patients classified as Stage III in TNM-8 are downstaged to Stage II in TNM-9, while most patients with Stage IVA in TNM-8 are reclassified as Stage III.\n* Finally, TNM-9 refines the M staging by dividing Stage IV into IVA (M1a, ≤3 metastatic lesions) and IVB (M1b, \\>3 metastatic lesions).\n\nStudies have shown that compared with TNM-8, TNM-9 exhibits significantly improved prognostic discriminatory ability, with obvious advantages in statistical validation-outperforming TNM-8 in terms of risk differentiation consistency, C-index, and Brier score. Meanwhile, Guo et al. proposed incorporating plasma EBV DNA into the TNM staging system based on 979 patients and constructing new subgroups via recursive partitioning analysis (RPA), which demonstrated better prognostic discriminatory ability than TNM-8. This study identified EBV DNA as an independent prognostic factor for progression-free survival (PFS) (HR=1.214, p=0.001), OS (HR=1.288, p\\<0.001), and distant metastasis-free survival (DMFS) (HR=1.386, p\\<0.001), and recommended 2000 copies/mL as the cutoff value for risk stratification. With the advancement of molecular diagnostic technologies, future staging systems may need to integrate molecular biomarkers.\n\nThe 9th edition AJCC/UICC Staging System was revised based on large-sample studies in high-incidence East Asian regions, significantly optimizing the definition of LA-NPC. However, the prognostic stratification efficacy of this system highly depends on the epidemiological characteristics of endemic regions (e.g., EBV positivity rate \\> 98%). Significant differences exist in dietary habits, lifestyles, and socioeconomic conditions between southern and eastern China, potentially leading to variations in the pathogenesis of NPC across different risk regions in China. For example, previous epidemiological studies have shown that the EBV positivity rate in endemic regions is slightly higher than in non-endemic regions. The uniqueness of NPC in non-endemic regions of China may profoundly affect the applicability of TNM-9 and the selection of treatment strategies. First, differences in treatment tolerance cannot be ignored; in addition, variations in environmental factors, accessibility to medical resources, and socioeconomic status may result in differences in treatment completion rates and toxicity profiles between LA-NPC patients in non-endemic and endemic regions. Therefore, the applicability of TNM-9 in populations from non-endemic regions still needs to be validated.\n\nIn non-endemic regions of NPC (e.g., Jiangsu, Zhejiang, and Anhui provinces), the survival outcomes and follow-up performance of locally advanced patients under TNM-9 and TNM-8 may differ from those in endemic regions. This study, leveraging multicenter long-term follow-up data, focuses on exploring the applicability of the TNM-9 staging system in non-endemic regions, aiming to fill gaps in research on the generalizability of TNM-9 and further clarify its stability and potential heterogeneity in populations from non-endemic regions.\n\nFurthermore, this study addresses the new changes in treatment strategies brought about by the updated staging system. One key change in TNM-9 is the restructuring of the LA-NPC patient population. The revision of N3 has expanded the scope of LA-NPC, making risk stratification of locally advanced disease even more critical. This restructuring, based on precise prognostic stratification, breaks away from the traditional TNM staging-based treatment decision-making model. It emphasizes the need to more clearly distinguish between low-risk and high-risk groups among LA-NPC patients and further explore optimized treatment intensity strategies corresponding to different risk levels.\n\nAccording to the CSCO Clinical Practice Guidelines for Head and Neck Tumors (2025), the treatment of LA-NPC is based on CCRT, and the combined application of IC, adjuvant chemotherapy, and immunotherapy should be explored. Current clinical studies indicate that CCRT is the standard treatment for LA-NPC, with cisplatin being the most commonly used drug. Sequential CCRT after IC is another treatment modality for LA-NPC; previous studies have shown that IC helps improve local control rates but does not significantly improve OS. Sequential adjuvant chemotherapy after CCRT is an alternative treatment modality for LA-NPC, but previous studies have reported suboptimal completion rates due to radiotherapy-related toxicity. The optimal adjuvant chemotherapy regimen, treatment cycles, and beneficiary populations remain to be determined, and the relationship between adjuvant therapy after CCRT and IC in terms of overall treatment efficacy also requires further research.\n\nIn recent years, various immune checkpoint inhibitors have been incorporated into clinical trials based on CCRT, including the full-course, neoadjuvant, adjuvant, and standalone adjuvant phases. Some studies have shown that these inhibitors may improve 2-3 year event-free survival (EFS) or PFS, but the optimal combination phase, neoadjuvant combination approach, duration of adjuvant therapy, and their impact on OS remain unclear. The following section highlights selected ongoing immunotherapy studies.\n\nImmunotherapy has become a transformative approach in cancer treatment, revolutionizing therapeutic strategies for various malignancies. NPC possesses a unique tumor microenvironment, characterized by abundant lymphocyte infiltration and a high PD-L1 expression rate (83%-92%), which provides a theoretical basis for immunotherapy in NPC. Preliminary results from the DIPPER study show that adjuvant PD-1 blockade with camrelizumab significantly improves EFS with manageable toxicity, highlighting its potential in the treatment of LA-NPC. Additionally, the completed phase III CONTINUUM trial provides pivotal evidence for the integration of immunotherapy into the management of high-risk LA-NPC, marking a milestone in this field. This study enrolled 425 patients with high-risk LA-NPC (30% Stage III, 70% Stage IVA), who were randomly assigned to receive either standard IC+CCRT or IC + sintilimab + CCRT + sintilimab maintenance therapy. After a median follow-up of 50.6 months, the sintilimab group demonstrated significantly superior EFS (the primary endpoint) compared to the standard treatment group. A subgroup analysis further revealed that patients with Stage N2/N3 derived particularly significant benefits, which is highly consistent with the high-risk nature of N3 (with advanced ENE) in TNM-9. The CONTINUUM trial confirmed that adding PD-1 inhibitors to standard IC+CCRT confers significant benefits in EFS, DMFS, and local recurrence-free survival (LRFS) for patients with high-risk LA-NPC, providing level III evidence for an intensified treatment model in this high-risk population. However, the increased toxicity associated with this regimen (especially immune-related adverse events) and its applicability in non-high-risk populations require careful evaluation.\n\nBased on the above background, this study focuses on NPC populations in non-endemic regions of China, leveraging long-term follow-up data and the 9th edition AJCC/UICC Staging System, with the following objectives:\n\n1. Validate the prognostic evaluation efficacy of the 9th edition AJCC/UICC Staging System in non-endemic regions; analyze differences in patient survival (OS, DFS, DMFS, PFS) between the 9th and 8th editions of the AJCC/UICC Staging System; and assess the consistency of risk stratification (C-index, AUC) of the 9th edition AJCC/UICC Staging System in populations from non-endemic regions.\n2. Explore subgroups of locally advanced patients under the 9th edition AJCC/UICC Staging System; evaluate the feasibility and potential clinical value of adjusting treatment intensity strategies in low-risk and high-risk populations.\n3. Explore subgroups of patients with N3 and lymph node metastasis (ENE) in non-endemic regions under the 9th edition AJCC/UICC Staging System; assess the accuracy of survival prediction and risk identification for these subgroups; and further analyze survival benefits associated with different treatment strategies.\n\nThe implementation of this study will provide detailed long-term follow-up data for NPC in non-endemic regions of China, filling research gaps in this field. Additionally, it may provide pivotal evidence for advancing the treatment decision-making framework, promoting clinical practices such as precise intensified treatment for high-risk patients and rational de-escalated treatment for intermediate-risk patients, thereby helping to bridge regional research gaps and improve patients\' quality of life.\n\nTo achieve the above objectives, the specific workflow is as follows:\n\n1. Patient Enrollment and Data Preparation:\n\n Patients with NPC were screened according to the aforementioned criteria at three centers: Jiangsu Cancer Hospital, Zhejiang Cancer Hospital, and Anhui Cancer Hospital. Original data (including name, hospital number, gender, age, treatment modality, and follow-up information) were uniformly named, cleaned, and coded. Baseline characteristic tables were constructed based on staging and data from internal/external hospitals.\n2. Staging Re-evaluation and Variable Organization:\n\n Multiple experts completed re-evaluation of staging according to the 9th and 8th editions of the AJCC/UICC Staging System. All variables-including study variables (e.g., age, T stage, N stage, targeted therapy) and confounding factors (e.g., treatment modality, gross tumor volume \\[GTV\\], residual lesions)-were organized into an analyzable format.\n3. Survival Analysis and Model Validation:\n\n Based on a minimum of 36 months of follow-up data, with OS, PFS, LRFS, and DMFS as outcomes, univariate screening was performed using Kaplan-Meier curves and log-rank tests. Subsequently, the prognostic performance of the TNM-9 staging system (C-index, time-dependent ROC, Brier score) was constructed and compared in Cox multivariate models. Finally, a risk score was developed based on independent predictors, and its stability was validated using Bootstrap resampling.\n4. Exploration of Treatment Strategies for Risk Subgroups:\n\nBased on the aforementioned extensive survival analyses, low-risk and high-risk subgroups of TNM-9-defined locally advanced patients were identified to explore the potential benefits of guiding targeted/immunotherapy for different risk groups.\n\nThis study is a retrospective cohort study, and all data were obtained from existing electronic medical record systems and radiotherapy/follow-up databases of three tertiary cancer hospitals (Jiangsu Cancer Hospital, Zhejiang Cancer Hospital, and Anhui Cancer Hospital). Researchers extracted relevant data from patients\' original medical records (including initial consultation information, chemoradiotherapy regimens, follow-up data, and imaging reports) and entered them into standardized electronic data collection forms (Excel spreadsheets) in a timely, complete, accurate, and clear manner. Case Report Forms (CRFs) were also completed to ensure that all data could be traced back to the original records.\n\nAlthough no electronic data capture (EDC) system was used, all electronic data collection forms were designed with unified variable field formats and restrictions on invalid inputs. A codebook (instruction document for data entry) was developed for researchers at each center to reference. Each study participant was identified by a unique research ID to ensure data anonymization and traceability.\n\nData verification was jointly conducted by the principal investigator and designated data managers at each center. The verification process included the following components:\n\n1. Eligibility Criteria Review: Individual verification of compliance with predefined inclusion/exclusion criteria to prevent incorrect enrollment or exclusion.\n2. Completeness Check: Confirmation that no core variables (e.g., staging, outcomes, survival time, treatment modality) were missing. If missing data were identified, original records were rechecked or the data were deemed ineligible for analysis.\n3. Logical Consistency Check: Verification of logical relationships (e.g., follow-up time cannot be earlier than the initial treatment date; date of death cannot be earlier than the end date of radiotherapy).\n4. Outlier Review: Flagging of values outside the normal range or with statistical anomalies, followed by verification with the respective center to confirm whether the values were entry errors.\n5. Data Lock Requirements: After all data were verified as correct, the data manager marked the dataset as the "final version," which was uniformly locked before proceeding to the statistical analysis phase. No modifications to locked data were allowed unless a written application and explanation of the modification reason were submitted, with a traceable record of changes.\n\nAfter completing data entry and verification as required, the CRFs of this study were archived and stored in numerical order, with a searchable catalog for reference. All electronic data files of the study were stored in categories, with multiple backups saved on different disks or storage media to prevent data loss or damage. All original records and study data will be retained for at least 10 years, in strict compliance with data confidentiality regulations and relevant medical information management requirements.\n\nThis study does not involve the transfer of data to countries or regions outside China, nor does it involve the collection, storage, or export of human genetic resources. It strictly adheres to the Regulations on the Management of Human Genetic Resources of the People\'s Republic of China\\* and other relevant laws and regulations. Study data are used exclusively for the purpose of this research, not for commercial use, and will not be disclosed to third parties, ensuring data privacy and compliance.\n\nThis study is a non-interventional, retrospective cohort study, and all participants were derived from real-world clinical data. Therefore, no prospective sample size calculation was performed. It is estimated that approximately 1500-1700 patients with locally advanced NPC diagnosed between 2011 and 2023 at the three centers will be enrolled. The sample size is sufficient to provide strong statistical power for analyzing the primary endpoint (OS), secondary endpoints (PFS, LRFS, DMFS), and multivariate analyses.\n\n1. Hypothesis Testing Principles\n\n Although no preset sample size was required, the following hypothesis testing principles were followed in statistical inference:\n * Null Hypothesis (H₀): The 9th edition TNM staging system cannot effectively distinguish between different survival risk groups among patients with locally advanced NPC in non-endemic regions (i.e., no significant survival differences between stages).\n * Alternative Hypothesis (H₁): The 9th edition TNM staging system can effectively distinguish between different survival risk groups among patients with locally advanced NPC in non-endemic regions (i.e., significantly different survival prognoses corresponding to different stages).\n\n All statistical inferences were set with a type I error rate (α) of 0.05 and a type II error rate (β) of 0.20 (i.e., 80% statistical power), using two-tailed tests. To control systematic errors and improve the reliability of statistical conclusions, the acceptable type I error rate (α) was set at 0.05 and the type II error rate (β) at 0.20, corresponding to 80% statistical power. All hypothesis tests used two-tailed tests unless otherwise specified.\n2. Statistical Methods Appropriate statistical tests were selected based on the types of predictor variables and outcome variables. The outcome variables in this study are all time-dependent (OS, PFS, LRFS, DMFS), and the independent variables include categorical variables (e.g., T/N stage) and continuous variables (e.g., age). Therefore, Kaplan-Meier curves combined with log-rank tests were used to compare survival differences between groups, and Cox proportional hazards models were further used for multivariate regression analysis-these are standard methods matching the variable types. For intergroup comparisons of baseline variables (non-outcome variables), methods such as chi-square tests, independent samples t-tests, and Wilcoxon rank-sum tests were used, all of which comply with statistical selection criteria based on variable types and distribution characteristics.\n\n Data analysis was primarily performed using R software (Version 4.5.0) for survival analysis, visualization, and model performance evaluation; partial data preprocessing and summary statistics were completed using SPSS Statistics (Version 30.0; IBM Corp.).\n * Quantitative Data (e.g., age, EBV-DNA level, GTV): Described using mean ± standard deviation or median (interquartile range), with statistical indicators selected based on normality and variance homogeneity.\n * Categorical Data (e.g., gender, T/N stage, treatment modality, use of targeted/immunotherapy): Described using frequencies and percentages.\n\n For intergroup comparisons:\n * For quantitative data: Independent samples t-tests were used if normality and variance homogeneity were satisfied; otherwise, Wilcoxon rank-sum tests (Mann-Whitney U tests) were used.\n * For categorical data: Chi-square tests were used; if the chi-square test assumptions were not met (e.g., excessively small expected frequencies), Fisher\'s exact tests were used.\n * For ordinal data (e.g., staging grades): Wilcoxon rank-sum tests were used. Except for the primary evaluation indicators, all statistical tests used two-tailed tests unless otherwise specified, with a two-tailed P\\<0.05 considered statistically significant.\n3. Survival Outcome Analysis Survival outcome variables included OS, LRFS, DMFS, and PFS. These variables are all time-dependent outcome variables. Kaplan-Meier methods were used to estimate survival rates and plot survival curves, and log-rank tests were used to compare intergroup differences.\n\nGiven the presence of multiple confounding factors in observational studies, multivariate analysis methods are ideal for adjustment. Common multivariate analysis methods include generalized linear models (e.g., logistic regression models, Cox models, Poisson models), linear mixed-effects models (LMM), and generalized linear mixed-effects models (GLMM). The selection of models depends primarily on the type of outcome variable. This study included multiple clinical variables that may affect survival outcomes; to account for confounding effects, univariate and multivariate analyses were performed using Cox proportional hazards regression models. Variables with P \\< 0.10 in univariate Cox models were first screened and then included in multivariate models to identify factors independently affecting OS (e.g., age, T stage, N stage, receipt of targeted therapy). The analysis results are reported as hazard ratios (HR), 95% confidence intervals (CI), and P values, with visualization via forest plots. Although some predictor variables are multicategorical (e.g., T stage, N stage, treatment modality)-with T/N stages being ordinal and treatment modality being nominal-Cox models can directly handle such variables without the need for additional ordinal or nominal regression models. This study does not involve binary or multicategorical outcome variables, nor does it use methods such as logistic regression, Poisson regression, LMM, or GLMM.\n\nThis study further employed multi-level statistical methods to achieve subgroup classification of locally advanced NPC. First, based on the multivariate Cox regression model combined with LASSO (Least Absolute Shrinkage and Selection Operator) and Bootstrap resampling techniques, three different risk stratification models (Models A/B/C) were established. The stability of the models was evaluated using variable selection frequency, while discriminatory validity was verified through Kaplan-Meier survival curves, Log-rank tests, and C-index. Results showed that age, HighRisk grouping, and targeted therapy were the most stable and critical prognostic factors. All three models effectively distinguished patients with different risk levels, among which Models B and C exhibited greater potential for refinement.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Patients aged 18 to 75 years, any sex, newly diagnosed with histologically confirmed nasopharyngeal carcinoma (NPC) from non-high-incidence areas in China (Jiangsu, Zhejiang, Anhui). All patients were treatment-naïve, completed high-quality MRI of the nasopharynx and neck, and received standard radiotherapy-based treatment. Eligible patients had adequate organ function, ECOG 0-1, Karnofsky score ≥70, and expected survival \\>3 months. Exclusion criteria included prior treatment (radiotherapy, chemotherapy, or surgery), severe comorbidities, uncontrolled infections, active autoimmune diseases needing immunosuppression, pregnancy or lactation, and incomplete or non-standard radiotherapy data.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Age 18-75 years old and gender\n* Long-term residence in a non-high prevalence area for nasopharyngeal cancer\n* Histologically confirmed primary nasopharyngeal cancer (without any treatment)\n* Completed MRI examination of nasopharynx and neck with image quality meeting the needs of imaging analysis\n* All receiving a standard comprehensive treatment plan with radiotherapy as the core\n* Adequate bone marrow, liver, and kidney function (meeting laboratory index thresholds)\n* ECOG 0-1, KPS ≥ 70 points, and life expectancy \\> 3 months\n* No previous history of immune disorders\n\nExclusion Criteria:\n\n* Received radiotherapy, chemotherapy, or surgery to the primary site or lymph nodes\n* Severe underlying disease (heart failure, renal failure, etc.), uncontrolled active infection, active autoimmune disease, or history of autoimmune disease requiring immunosuppressive therapy\n* Pregnant or breastfeeding females\n* Irregular radiotherapy or missing treatment data'}, 'identificationModule': {'nctId': 'NCT07088861', 'briefTitle': 'Validation of the 9th AJCC Staging System for NPC in Non-High-Incidence Areas in China', 'organization': {'class': 'OTHER', 'fullName': 'Jiangsu Cancer Institute & Hospital'}, 'officialTitle': 'Validation and Analysis of the 9th Edition AJCC/UICC Staging System for Nasopharyngeal Carcinoma in Non-High-Incidence Areas in China - A Multicentre Retrospective Clinical Study', 'orgStudyIdInfo': {'id': 'KM-2025-123'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Overall Cohort', 'description': 'All eligible patients from three centers in Jiangsu, Zhejiang, and Anhui provinces. Used for overall staging validation and prognostic analysis.'}, {'label': 'Internal Validation Cohort', 'description': 'Patients from Jiangsu Cancer Hospital. Used for model training and internal validation.'}, {'label': 'External Validation Cohort', 'description': 'Patients from Zhejiang Cancer Hospital and Anhui Cancer Hospital. Used for external validation of staging performance.'}]}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Xia He, Professor, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Institute of Cancer Research'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': 'Due to patient privacy concerns and ethical restrictions, individual participant data (IPD) will not be shared publicly. The data contain sensitive personal health information protected by institutional and national regulations. Sharing is limited to authorized study personnel and collaborators under strict confidentiality agreements.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Lirong Wu', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'associate professor, Department of Radiotherapy, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Institute of Cancer Research', 'investigatorFullName': 'Lirong Wu', 'investigatorAffiliation': 'Jiangsu Cancer Institute & Hospital'}}}}